NICE says yes and no to Amgen's Xgeva
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, maintains that Amgen's Xgeva (denosumab) would not be cost-effective for preventing skeletal-related events in adults with bone metastases from prostate cancer on the National Health Service. However, according to today's final appraisal determination, it still looks set to recommend the drug for preventing SREs in other patients.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.